Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.86 |
| ▸ | RAB9A | P51151 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | RORC | P51449 | 1/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501818 | 0.93 | RAB9A (0.81) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL17115744 | 0.93 | NPC1 (0.81) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL12010918 | 0.93 | RAB9A (0.81) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL2564890 | 0.93 | NPC1 (1.00) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| Iodide SCHEMBL30758553 | 0.91 | NPC1 (0.96) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL7513604 | 0.90 | TRPV1 (0.83) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL19501822 | 0.89 | SIRT1 (0.74) | NPC1RAB9ALMNAPTGS1MEN1 | |
| SCHEMBL27924242 | 0.88 | NPC1 (0.90) | NPC1RAB9ALMNAPTGS1TRPV1 | |
| SCHEMBL11730950 | 0.87 | NPC1 (0.77) | NPC1RAB9APTGS1TRPV1MAPT | |
| SCHEMBL7519747 | 0.87 | MAPT (0.82) | NPC1RAB9ALMNAPTGS1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483582-B | Aza-carbene-palladium complex crystal, synthesis method thereof and application thereof in preparing amide compound | 陕西师范大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-108504094-B | Polyimide precursor solution and polyimide film | 富士胶片商业创新有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114276270-A | Synthesis method of compound with amido bond | 湖北文理学院 | 2022-04-05 | — | — | CN | disclosed |
| EP-2791121-B1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20100069443-A1 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-7071199-B1 | Kinase inhibitors as therapeutic agents | ABBOTT GMBH & CCO. KG (DE) | 2006-07-04 | — | — | US | disclosed |
| EP-0725302-B1 | A process of producing a polyimide block copolymer | JAPAN SYNTHETIC RUBBER CO LTD (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-5672750-A | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride | EASTMAN CHEMICAL COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0725302-A2 | A process of producing a polyimide block copolymer | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069443-A1 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY | PTGS1, PTGS2, PTGIS | NPC1 3504/4885RAB9A 3360/4885LMNA 4467/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.